This Amendment No. 3
(Amendment No. 3) is filed by PDL BioPharma, Inc. (the Reporting Person) to amend and supplement the Schedule 13D originally filed on April 18, 2019 (as amended to date, the
Schedule 13D), relating to the shares of common stock, par value $0.0001 per share (the Common Stock), of Evofem BioSciences, Inc., a Delaware corporation (the Issuer).
Item 5.
|
Interest in Securities of the Issuer
|
Item 5(a)-(c) of the Schedule 13D is amended and restated in its entirety as follows:
(a) The Reporting Person is the record holder of, and has the sole power to vote or to direct the vote and sole power to
dispose or to direct the disposition of 16,666,668 shares of Common Stock (including 1,666,667 shares of Common Stock subject to warrants that will become exercisable on October 11, 2019 (the April Warrants) and 1,666,667
shares of Common Stock subject to warrants that will become exercisable on December 10, 2019 (the June Warrants)), which represents 33.4% of the Issuers Common Stock outstanding, based on 46,601,058 shares of Common
Stock outstanding as of July 31, 2019 and assuming the exercise of the April Warrants and the June Warrants.
(b) The Reporting Person is a publicly traded company with common stock listed on the Nasdaq stock market. The
Reporting Person is the direct beneficial owner of 16,666,668 shares of Common Stock, which includes 1,666,667 shares of Common Stocks subject to the April Warrants and 1,666,667 shares of Common Stock subject to the June Warrants, with respect to
which it has sole voting and dispositive power.
(c) Neither the Reporting Person nor any Related Person has
effected any transactions in the Issuers Common Stock since the filing of Amendment No. 2.
3